GC/MSD, GC/MS/MS, HeadSpace, GC/QQQ
IndustriesPharma & Biopharma
ManufacturerShimadzu
Importance of Topic
N-Nitrosodimethylamine (NDMA) and N-Nitrosodiethylamine (NDEA) are low-molecular-weight dialkylnitrosamines classified as probable human carcinogens. These compounds arise as by-products in pesticide, rubber, dye and pharmaceutical manufacturing, and can contaminate active pharmaceutical ingredients (APIs) and finished drug products. Recent recalls of sartans in Europe and the US highlighted the need for ultra-sensitive, robust analytical methods to ensure patient safety and regulatory compliance.
Objectives and Study Overview
The primary aim of this study was to develop and validate a headspace gas chromatography-tandem mass spectrometry (HS-GCMS/MS) method for the quantitation of trace levels of NDMA and NDEA in pharmaceutical APIs (valsartan, losartan and olmesartan medoxomil). The method employs multiple reaction monitoring (MRM) for high specificity and targets a calibration range of 1.0–50.0 µg/L (ppb).
Used Instrumentation
- Shimadzu GCMS-TQ8040 NX triple-quadrupole mass spectrometer
- HS-20 headspace autosampler
- Stabilwax DA capillary column (30 m × 0.32 mm ID, 1.0 µm film)
- Helium carrier gas, constant linear velocity mode
- N,N-Dimethyl sulfoxide (DMSO) as diluent
Methodology and Instrumentation
Sample preparation involved dissolving APIs in DMSO to a 2 % w/v solution in 20 mL headspace vials. A standard mixture of NDMA and NDEA (Restek®) was used to establish calibration curves (1.0–50.0 µg/L). Headspace conditions included a loop injection (1 mL), oven at 160 °C, sample line at 165 °C and transfer line at 175 °C. GC temperature programming began at 40 °C, ramped to 230 °C. MS operated in electron ionization mode (70 eV) and MRM mode. Precursor and product ions were optimized using Shimadzu’s MRM optimization tool; collision energies ranged from 5 to 37 eV.
Key Results and Discussion
- Linearity: Six-point calibration (1–50 ppb) for both analytes yielded r2 ≥ 0.999.
- Limit of Quantitation: 1 ppb for NDMA (S/N 30, RSD 8.9 %) and NDEA (S/N 238, RSD 8.2 %).
- Precision: Six replicate injections at LOQ and a mid-level standard (10 ppb) showed RSD ≤ 8.2 %.
- Spike Recovery: API samples spiked at 1.0, 10.0 and 50.0 ppb gave recoveries between 85.8 % and 119.4 %, demonstrating accuracy across matrices.
Benefits and Practical Applications
This HS-GCMS/MS approach offers:
- High sensitivity and selectivity for genotoxic impurities at sub-ppb levels.
- Rapid analysis (< 30 min cycle time) with minimal sample handling.
- Robust quantitation suitable for routine QC of pharmaceutical substances.
Future Trends and Potential Applications
Emerging opportunities include:
- Extension of the method to additional nitrosamine contaminants in diverse drug products.
- Integration with automated data processing for real-time quality monitoring.
- Miniaturized headspace modules for higher throughput and reduced solvent use.
Conclusion
A rapid, reliable HS-GCMS/MS method was successfully developed for trace determination of NDMA and NDEA in sartans. The combination of optimized MRM transitions, headspace sampling and fast scanning enables high-throughput screening of genotoxic impurities, supporting regulatory compliance and quality assurance in pharmaceutical manufacturing.
Reference
Shimadzu Analytical (India) Pvt. Ltd. Application Note No. GC-23-ADI-062, October 2018.
Content was automatically generated from an orignal PDF document using AI and may contain inaccuracies.